Splenectomy in the accelerated or blastic phase of chronic myelogenous leukemia: A single-institution, 25-year experience

Michael Bouvet, Gildy V. Babiera, Paula M. Termuhlen, Jeane P. Hester, Hagop M. Kantarjian, Raphael E. Pollock

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background. Patients in the accelerated or blastic phases of chronic myelogenous leukemia (CML) often have painful splenomegaly and secondary thrombocytopenia. We tested the hypothesis that splenectomy can be performed with minimal complications in advanced CML, thereby alleviating pain, reversing thrombocytopenia, and minimizing transfusion requirements. Methods. We reviewed the records of 53 patients in the accelerated or blastic phases of CML who undo went splenectomy between 1970 and 1995 at the U. T. M. D. Anderson Cancer Center. Results. Twenty-eight patients were in accelerated phase and 25 in blastic phase at the time of splenectomy. The most common indications for splenectomy were symptomatic splenomegaly (median splenic weight, 1000 gm; range, 120 to 6700 gm) or thrombocytopenia (platelet count less than 100,000/μl) or both. There was 1 death within 30 days of splenectomy. The preoperative platelet count increased 3. 72-fold ± 0.53- fold (mean ± SEM) by postoperative day 7 (p < 0.001; paired t test). Patients with transfusion-dependent thrombocytopenia had significantly fewer platelet and red blood cell transfusions in the 6 months after splenectomy than in the 6 months before splenectomy (p = 0.016; sign test). Conclusions. Splenectomy can be performed with minimal morbidity and mortality in advanced CML, thereby relieving symptomatic splenomegaly, reversing thrombocytopenia, and minimizing transfusion requirements.

Original languageEnglish (US)
Pages (from-to)20-25
Number of pages6
JournalSurgery
Volume122
Issue number1
DOIs
StatePublished - Jul 1997

Fingerprint

Leukemia, Myeloid, Chronic Phase
Splenectomy
Thrombocytopenia
Splenomegaly
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Platelet Count
Erythrocyte Transfusion
Blood Platelets
Morbidity
Weights and Measures
Pain
Mortality

Cite this

Splenectomy in the accelerated or blastic phase of chronic myelogenous leukemia : A single-institution, 25-year experience. / Bouvet, Michael; Babiera, Gildy V.; Termuhlen, Paula M.; Hester, Jeane P.; Kantarjian, Hagop M.; Pollock, Raphael E.

In: Surgery, Vol. 122, No. 1, 07.1997, p. 20-25.

Research output: Contribution to journalArticle

Bouvet, Michael ; Babiera, Gildy V. ; Termuhlen, Paula M. ; Hester, Jeane P. ; Kantarjian, Hagop M. ; Pollock, Raphael E. / Splenectomy in the accelerated or blastic phase of chronic myelogenous leukemia : A single-institution, 25-year experience. In: Surgery. 1997 ; Vol. 122, No. 1. pp. 20-25.
@article{8acb54af0d47472686f082322ef7142c,
title = "Splenectomy in the accelerated or blastic phase of chronic myelogenous leukemia: A single-institution, 25-year experience",
abstract = "Background. Patients in the accelerated or blastic phases of chronic myelogenous leukemia (CML) often have painful splenomegaly and secondary thrombocytopenia. We tested the hypothesis that splenectomy can be performed with minimal complications in advanced CML, thereby alleviating pain, reversing thrombocytopenia, and minimizing transfusion requirements. Methods. We reviewed the records of 53 patients in the accelerated or blastic phases of CML who undo went splenectomy between 1970 and 1995 at the U. T. M. D. Anderson Cancer Center. Results. Twenty-eight patients were in accelerated phase and 25 in blastic phase at the time of splenectomy. The most common indications for splenectomy were symptomatic splenomegaly (median splenic weight, 1000 gm; range, 120 to 6700 gm) or thrombocytopenia (platelet count less than 100,000/μl) or both. There was 1 death within 30 days of splenectomy. The preoperative platelet count increased 3. 72-fold ± 0.53- fold (mean ± SEM) by postoperative day 7 (p < 0.001; paired t test). Patients with transfusion-dependent thrombocytopenia had significantly fewer platelet and red blood cell transfusions in the 6 months after splenectomy than in the 6 months before splenectomy (p = 0.016; sign test). Conclusions. Splenectomy can be performed with minimal morbidity and mortality in advanced CML, thereby relieving symptomatic splenomegaly, reversing thrombocytopenia, and minimizing transfusion requirements.",
author = "Michael Bouvet and Babiera, {Gildy V.} and Termuhlen, {Paula M.} and Hester, {Jeane P.} and Kantarjian, {Hagop M.} and Pollock, {Raphael E.}",
year = "1997",
month = "7",
doi = "10.1016/S0039-6060(97)90259-2",
language = "English (US)",
volume = "122",
pages = "20--25",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Splenectomy in the accelerated or blastic phase of chronic myelogenous leukemia

T2 - A single-institution, 25-year experience

AU - Bouvet, Michael

AU - Babiera, Gildy V.

AU - Termuhlen, Paula M.

AU - Hester, Jeane P.

AU - Kantarjian, Hagop M.

AU - Pollock, Raphael E.

PY - 1997/7

Y1 - 1997/7

N2 - Background. Patients in the accelerated or blastic phases of chronic myelogenous leukemia (CML) often have painful splenomegaly and secondary thrombocytopenia. We tested the hypothesis that splenectomy can be performed with minimal complications in advanced CML, thereby alleviating pain, reversing thrombocytopenia, and minimizing transfusion requirements. Methods. We reviewed the records of 53 patients in the accelerated or blastic phases of CML who undo went splenectomy between 1970 and 1995 at the U. T. M. D. Anderson Cancer Center. Results. Twenty-eight patients were in accelerated phase and 25 in blastic phase at the time of splenectomy. The most common indications for splenectomy were symptomatic splenomegaly (median splenic weight, 1000 gm; range, 120 to 6700 gm) or thrombocytopenia (platelet count less than 100,000/μl) or both. There was 1 death within 30 days of splenectomy. The preoperative platelet count increased 3. 72-fold ± 0.53- fold (mean ± SEM) by postoperative day 7 (p < 0.001; paired t test). Patients with transfusion-dependent thrombocytopenia had significantly fewer platelet and red blood cell transfusions in the 6 months after splenectomy than in the 6 months before splenectomy (p = 0.016; sign test). Conclusions. Splenectomy can be performed with minimal morbidity and mortality in advanced CML, thereby relieving symptomatic splenomegaly, reversing thrombocytopenia, and minimizing transfusion requirements.

AB - Background. Patients in the accelerated or blastic phases of chronic myelogenous leukemia (CML) often have painful splenomegaly and secondary thrombocytopenia. We tested the hypothesis that splenectomy can be performed with minimal complications in advanced CML, thereby alleviating pain, reversing thrombocytopenia, and minimizing transfusion requirements. Methods. We reviewed the records of 53 patients in the accelerated or blastic phases of CML who undo went splenectomy between 1970 and 1995 at the U. T. M. D. Anderson Cancer Center. Results. Twenty-eight patients were in accelerated phase and 25 in blastic phase at the time of splenectomy. The most common indications for splenectomy were symptomatic splenomegaly (median splenic weight, 1000 gm; range, 120 to 6700 gm) or thrombocytopenia (platelet count less than 100,000/μl) or both. There was 1 death within 30 days of splenectomy. The preoperative platelet count increased 3. 72-fold ± 0.53- fold (mean ± SEM) by postoperative day 7 (p < 0.001; paired t test). Patients with transfusion-dependent thrombocytopenia had significantly fewer platelet and red blood cell transfusions in the 6 months after splenectomy than in the 6 months before splenectomy (p = 0.016; sign test). Conclusions. Splenectomy can be performed with minimal morbidity and mortality in advanced CML, thereby relieving symptomatic splenomegaly, reversing thrombocytopenia, and minimizing transfusion requirements.

UR - http://www.scopus.com/inward/record.url?scp=0030839138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030839138&partnerID=8YFLogxK

U2 - 10.1016/S0039-6060(97)90259-2

DO - 10.1016/S0039-6060(97)90259-2

M3 - Article

C2 - 9225910

AN - SCOPUS:0030839138

VL - 122

SP - 20

EP - 25

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 1

ER -